Press Releases

GlobeNewswire, Inc.

Austin, TX, USA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Die Cut Lids Market Size, Trends and Insights By Material Type (Aluminum Lids, Plastic Lids, Paper-Based Lids, Others), By Seal...

GlobeNewswire, Inc.

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™)...

EIN Presswire

YANTAI, SHANDONG, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- The modern retail environment functions as a visual economy where a product's exterior often determines its market success.

EIN Presswire

YANTAI, SHANDONG, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- The global aluminum beverage packaging sector is undergoing a measurable shift.

EIN Presswire

YANTAI, SHANDONG, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- The beverage packaging industry in 2026 has transitioned from a focus on mere containment to a sophisticated pursuit of consumer engagement and sensory experience.

EIN Presswire

YANTAI, SHANDONG, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- The global beverage industry has undergone a radical shift in its procurement strategies over the last few years.

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a...

U.S. Food and Drug Administration

Summary Company Announcement Date: August 22, 2026 FDA Publish Date: August 22, 2026 Product Type: Food & Beverages Reason for Announcement: Recall Reason Description Potential to be contaminated with Salmonella and Shiga toxin-producing...

EIN Presswire

XI'AN, SHAANXI, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- Beverage formulation has raised the bar for matcha.

GlobeNewswire, Inc.

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today...

EIN Presswire

Company Continues Transition into AI and Digital Technology Holding Company while looking for other Opportunities Alliance Creative Group, Inc. (OTCMKTS:ACGX) CHICAGO, IL, UNITED STATES, August 12, 2026 /⁨EINPresswire.com⁩/ -- Alliance Creative...

GlobeNewswire, Inc.

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark...

EIN Presswire

SHIJIAZHUANG, HEBEI, CHINA, August 12, 2026 /⁨EINPresswire.com⁩/ -- For buyers evaluating a China Leading Glass Food Container Manufacturer for microwave- and oven-oriented programs, IKOO GLASS provides a high-borosilicate platform combining...

GlobeNewswire, Inc.

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M...

GlobeNewswire, Inc.

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30...

GlobeNewswire, Inc.

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and...

GlobeNewswire, Inc.

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund...

GlobeNewswire, Inc.

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026...

GlobeNewswire, Inc.

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June;...

GlobeNewswire, Inc.

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA...